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A B S T R A C T
Background: Serum biomarkers may inform and improve care in traumatic brain injury (TBI). We aimed to
correlate serum biomarkers with clinical severity, care path and imaging abnormalities in TBI, and explore
their incremental value over clinical characteristics in predicting computed tomographic (CT) abnormalities.
Methods: We analyzed six serum biomarkers (S100B, NSE, GFAP, UCH-L1, NFL and t-tau) obtained <24 h
post-injury from 2867 patients with any severity of TBI in the Collaborative European NeuroTrauma Effec-
tiveness Research (CENTER-TBI) Core Study, a prospective, multicenter, cohort study. Univariable and multi-
variable logistic regression analyses were performed. Discrimination was assessed by the area under the
receiver operating characteristic curve (AUC) with 95% confidence intervals.
Findings: All biomarkers scaled with clinical severity and care path (ER only, ward admission, or ICU), and
with presence of CT abnormalities. GFAP achieved the highest discrimination for predicting CT abnormalities
(AUC 089 [95%CI: 087090]), with a 99% likelihood of better discriminating CT-positive patients than clin-
ical characteristics used in contemporary decision rules. In patients with mild TBI, GFAP also showed incre-
mental diagnostic value: discrimination increased from 084 [95%CI: 083086] to 089 [95%CI:
087090] when GFAP was included. Results were consistent across strata, and injury severity. Combina-
tions of biomarkers did not improve discrimination compared to GFAP alone.
Interpretation: Currently available biomarkers reflect injury severity, and serum GFAP, measured within 24 h
after injury, outperforms clinical characteristics in predicting CT abnormalities. Our results support the fur-
ther development of serum GFAP assays towards implementation in clinical practice, for which robust clini-
cal assay platforms are required.
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1. Introduction
The delivery of precision medicine for traumatic brain injury (TBI)
requires objective tools to identify disease phenotypes and to guide
clinical decisions [1]. Clinical assessment and computerized tomogra-
phy (CT) of the head form the diagnostic cornerstone in clinical prac-
tice, but a need remains for more detailed disease classification
utilizing a multidimensional approach. Moreover, indiscriminate use
of CT, resulting in high costs, and increased recognition of risks of
radiation exposure have called for more selective use of CT scanning
in patients with milder forms of TBI [1,2]. Various clinical decision
rules (CDR) have been developed for this purpose [37], but their
adoption in clinical practice is variable.
A major focus of recent research has been on the potential of bio-
markers to improve diagnosis and patient characterization, and
enable tailored management [8]. Several publications have provided
extensive evidence of analytical and early clinical validity of various
biomarkers, and documented efforts to achieve regulatory clearance
[9]. However, the development of clinical algorithms and guidelines
which integrate biomarker measurements to inform decision-making
has been inconsistent, partial and inconclusive [10]. S100 calcium-
binding protein B (S100B), a biomarker of astroglial breakdown, has
been implemented in the Scandinavian TBI Guidelines [11], but is sel-
dom used outside the Nordic countries and with sub-optimal perfor-
mance in real-world conditions [12]. The pivotal ALERT-TBI study
showed high sensitivity for the combination of astroglial (glial fibril-
lary acidic protein [GFAP]) and neuronal (ubiquitin C-terminal hydro-
lase L1 [UCH-L1]) biomarker blood levels measured within 12 h after
injury in triaging the need for CT scanning [13], but did not address
the added value compared to clinical characteristics used in CDRs, or
explore its value relative to S100B [14]. More in general, few studies
have examined the incremental value of biomarkers beyond clinical
characteristics.
As a consequence, uncertainty exists how biomarkers, either sin-
gly or in combination, can best improve existing decision-making
and processes of care, creating a barrier to widespread implementa-
tion and adoption of these tests in medical practice. Nevertheless,
blood-based biomarkers provide objective information, offer addi-
tional risk stratification and hold potential to inform personalized
interventions.
Research in context
Evidence before this study
Blood-based biomarkers hold potential for informing and sub-
stantially improving the clinical management of patients with
traumatic brain injury (TBI). To date, however, only one bio-
marker (S100B) has been integrated into some national guide-
lines for triaging the need to perform computerized
tomography scanning (CT scan) of the brain in patients with
mild TBI. The superiority or incremental benefit of biomarkers
beyond canonical clinical variables used in CT prediction rules
has not convincingly been demonstrated. Moreover, uncer-
tainty exists as to how single or multi-biomarker tests perform.
We conducted a living systematic review and meta-analysis to
quantify the ability of blood biomarkers with advanced analyti-
cal and clinical validity (GFAP, UCH-L1, NSE, S100B, t-tau and
NFL) to predict the presence of traumatic abnormalities on
head CT scanning in the acute clinical setting. We screened
MEDLINE, Embase, EBM Reviews and Cochrane Library for rele-
vant articles on October 25, 2016, and, subsequently updated
the results by monitoring the literature every 3 months. Syn-
thesis of these data indicated that only S100B had high sensitiv-
ity and negative predictive value (NPV) and could be used to
rule out the need for acute CT scanning. The evidence to sup-
port use of other emerging markers was limited and insufficient
to warrant clinical application. Recently, the ALERT-TBI trial
(1959 participants), published in 2018, showed that GFAP and
UCH-L1, in combination, discriminated between patients with
and without CT abnormalities. Results from the TRACK-TBI
study in the US, highlighted the potential of biomarkers as a
screening tool for MRI abnormalities in patients with normal
CT findings. However, the clinical utility of these biomarkers
still remains uncertain. Further work is needed to determine
the most effective and efficient biomarker or multimarker strat-
egy for integration into clinical care.
Added value of this study
We use data from a well-characterized multicenter cohort of
2867 patients with TBI to provide the first evidence of medical
utility of blood biomarkers beyond standard of care-based clini-
cal characteristics. Our results support potential for their adop-
tion into clinical use to inform and improve decision making in
current practice. In particular, we corroborate and extend
recent results regarding the diagnostic performance of GFAP,
showing that GFAP captures the greatest discriminatory infor-
mation, performing as well as a combination of all markers and
adding value to clinical characteristics. We believe this is the
largest study to simultaneously assess and compare the diag-
nostic performance of a panel of 6 biomarkers reflecting dis-
tinct types of injury and pathophysiological mechanisms,
across a population of patients with a full range of TBI severities
and wide range of injury patterns.
The assessment of the utility of biomarker measurements in
individual care pathways, as defined in CENTER-TBI, allows us
to explore their use in a range of contexts of care. This ensures
the robustness and generalizability of our estimates derived
from real-world patient population and clinical scenarios, while
confirming the generation of actionable information for
clinicians. Comparison of our results with those from other
studies shows similar trends, but also highlights between-plat-
form inconsistencies in assay calibration and reported bio-
marker values.
Implications of all the available evidence
This study provides the most exhaustive and comparable
assessment to date of the six best-validated TBI biomarkers,
demonstrating their potential utility in refining diagnosis, tri-
age, injury characterization, and clinical care in TBI, beyond cur-
rently established clinical variables. We highlight the potential
role of GFAP as part of a comprehensive triage strategy and con-
sider it to be best positioned for implementation into medical
practice and incorporation in clinical decision algorithms.
Robust clinical use assay platforms are a prerequisite for such
clinical implementation.
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The CENTER-TBI Core study (Collaborative European Neuro-
Trauma Effectiveness Research: www.center-tbi.eu) was designed to
advance multimodal characterization and classification in TBI
[15,16]. Within this unique framework, in which patients were strati-
fied by care path, we aimed to determine the relation  and their rel-
ative performance  of a panel of biomarkers, assessed within 24 h of
injury, with clinical severity, care pathways and presence of CT
abnormalities across the entire injury spectrum of TBI. We further
aimed to explore the incremental value of biomarkers compared to
established clinical characteristics in predicting the presence of CT
abnormalities.
2. Materials and methods
2.1. Study design and participants
The CENTER-TBI Core study is a prospective observational clinical
and biomarker study of patients with TBI, conducted in 65 clinical
sites from 17 European countries and Israel between December 19,
2014, and December 17, 2017. The study was registered with Clinical-
Trials.gov (NCT02210221). Details of protocol and clinical data have
been previously published [15,16]. In brief: patients with all severi-
ties of TBI presenting to a study center within 24 h of injury and
scheduled for CT scanning were enrolled, stratified by care path
(emergency department [ER], admission [Adm] and intensive care
unit [ICU]). The only exclusion criterion was severe pre-existing neu-
rological disorder.
The study was conducted in accordance with all relevant laws of
the EU if directly applicable or of direct effect and all relevant laws of
the country where the Recruiting sites were located, including but
not limited to, the relevant privacy and data protection laws and reg-
ulations (the “Privacy Law”), the relevant laws and regulations on the
use of human materials, and all relevant guidance relating to clinical
studies from time to time in force including, but not limited to the
ICH Harmonized Tripartite Guideline for Good Clinical Practice
(CPMP/ICH/135/95) (“ICH GCP”) and the World Medical Association
Declaration of Helsinki entitled “Ethical Principles for Medical
Research Involving Human Subjects”. Informed Consent by the
patients and/or the legal representative/next of kin was obtained for
all patients and documented in the e-CRF. The use of the biological
samples was in accordance with the terms of the informed consent.
The list of sites, Ethical Committees, approval numbers and approval
dates can be found on https://www.center-tbi.eu/project/ethical-
approval.
The study is reported in accordance with the STROBE recommen-
dations (see Supplementary material).
In this analysis, which was pre-specified in the Description of
Work for CENTER-TBI, we focused on a cohort of patients in whom
(1) blood sampling within 24 h of injury, and (2) an early CT scan
were available (Fig. 1).
2.2. Procedures
Blood samples for determination of biomarkers were collected
using gel-separator tubes for serum, and centrifuged within 60
minutes. Serum was processed, aliquoted (8 £ 0¢5 ml), and stored at
80 °C locally until shipment on dry ice to the central CENTER-TBI
biobank (Pecs, Hungary).
We assayed six biomarkers: S100B, neuron-specific enolase (NSE),
GFAP, UCH-L1, neurofilament protein-light (NFL), and total tau (t-
tau). S100B and NSE were measured with a clinical-use automated
system, using an electrochemiluminescence immunoassay kit (ECLIA)
(Elecsys S100 and Elecsys NSE assays) run on the e 602 module of
Cobas 8000 modular analyzer (Roche Diagnostics, Mannheim, Ger-
many) at the University of Pecs (Pecs, Hungary). Serum GFAP, UCH-
L1, NFL and t-tau were analyzed with an ultrasensitive immunoassay
using digital array technology (Single Molecule Arrays, SiMoA)-based
Human Neurology 4-Plex B assay (N4PB) run on the SR-X benchtop
assay platform (Quanterix Corp., Lexington, MA) at the University of
Florida (Gainesville, Florida). Unique aliquots were used for analyses
on the two platforms to avoid repeated freeze-thaw cycles, and ana-
lyzed in one round of experiments using the same batch of reagents
by qualified laboratory technicians blinded to clinical information.
Replicate assays were performed on a subset of samples with a bal-
anced distribution across strata. The percent of replicates performed
were 4¢3% for the SiMoA platform and 5¢7% for the Roche platform 
these numbers were selected to fit within the assaying logistics and
assay work flow for the full assay runs on the respective platforms.
Clinical data, including variables used in clinical decision rules
(CDRs) for triaging CT scanning (Supplementary Table 1), were col-
lected using a web-based electronic case report form (eCRF), with
variables coded in accordance with the Common Data Elements
(CDE) scheme (https://commondataelements.ninds.nih.gov/).
All patients underwent head CT examinations according to local
protocols. Imaging studies were transmitted to a central repository
(Icometrix, Leuven) for structured reporting according to the NINDS
TBI-CDEs. Central reviewers were blinded to clinical information,
except gender, age, and care path. The presence of any traumatic
intracranial abnormality on CT was considered a positive scan. Skull
fractures in isolation were not considered as intracranial abnormality.
MR scans performed according to study protocol were obtained in
a subgroup of 502 patients. We report on 152 of these patients who
had a negative CT scan on presentation.
2.3. Statistical analysis
Baseline characteristics were summarized using standard descrip-
tive statistics. Continuous variables are presented as median (inter-
quartile range) and categorical variables as absolute frequencies and
percentages. BlandAltman plots were made for replicate assays. The
coefficient of variation was calculated on the log transformed values
and expressed as percentage.
Relations of biomarkers to clinical severity (GCS) and care path
were displayed in tabular and graphical formats. Correlations
between biomarkers were visualized by scatterplots and quantified
using Spearman’s rank correlation coefficients. Distributions of bio-
marker levels for patients with intracranial abnormalities were com-
pared to those without abnormalities with MannWhitney U tests.
We explored adjusting for multiple testing (Bonferroni, false discov-
ery rate), but only reported these results when they changed the
interpretation of the results.
Multiple imputation of missing characteristics was performed
using the mice package [17], assuming a missing at random mecha-
nism. Clinical characteristics with >50% completion, CT positivity
and biomarkers were included in the imputation model. Predictive
mean matching was used for continuous data, logistic regression
for binary data, and polytomous regression for categorical data.
Fifty imputed datasets were created, with results summarized
according to Rubin’s rules [18]. The diagnostic performance of bio-
markers, separately and in combination to identify patients with
positive CT findings was assessed with logistic regression. We
allowed for non-linear effects of log transformed biomarkers using
restricted cubic splines with 3 degrees of freedom. From these
models, we derived estimates of the area under the ROC curves
(AUC, or c-statistic). A bootstrap resampling procedure with 200
repetitions was applied to calculate 95% confidence intervals (CIs).
Univariable and multivariable analysis, adjusting for clinical char-
acteristics, was performed.
The clinical characteristics derived from CDRs were included in
the multivariable analysis as they are presented in Supplementary
Table 2. Continuous variables were included without categorization
to fully capture the diagnostic information they contain. In case
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variables were non-informative (GCS in the GCS 15 sensitivity analy-
sis, or depressed skull fracture in the ER stratum), they were excluded
from the model.
The performance of biomarkers compared to clinical characteris-
tics in the univariable analysis was explored by a bootstrapping pro-
cedure that included 1000 repetitions. The percentage of repetitions
where a univariable model with the biomarker outperformed (higher
c-statistic) a multivariable model with all clinical characteristics used
in current CDRs was calculated.
Predictions based on clinical characteristics were compared to
predictions with biomarkers added to the clinical variables and
results visualized using reclassification plots [19].
Fig. 1. Flow chart for biomarker cohort in the CENTER TBI core study.
Table 1
Characteristics of biomarker cohort (n=2867) in the CENTER-TBI core study.
N complete Overall (n=2867) ER (n=636) Admission (n=900) ICU (n=1331)
Demographic characteristics
Age (median [IQR]) 2867 49 [30, 66] 48 [30, 65] 53 [33, 68] 48 [30, 64]
>65 years (%) 735 (25¢6) 153 (24¢1) 266 (29¢6) 316 (23¢7)
Male sex (%) 2867 1948 (67¢9) 354 (55¢7) 619 (68¢8) 975 (73¢3)
Cause of injury
Cause of injury 2711
Road traffic incident (%) 1098 (38¢3) 204 (32¢1) 295 (32¢8) 599 (45¢0)
Incidental fall (%) 1264 (44¢1) 317 (49¢8) 436 (48¢4) 511 (38¢4)
Clinical presentation
GCS baseline (median [IQR]) 2775 15 [10, 15] 15 [15, 15] 15 [14, 15] 10 [4, 14]
Severe (38) (%) 601 (21¢0) 1 (0¢2) 7 (0¢8) 593 (44¢6)
Moderate (912) (%) 222 (7¢7) 2 (0¢3) 28 (3¢1) 192 (14¢4)
Mild (1314) (%) 457 (15¢9) 38 (6¢0) 202 (22¢4) 217 (16¢3)
Mild (15) (%) 1494 (52¢1) 589 (92¢6) 643 (71¢4) 262 (19¢7)
Pupillary reactivity 2732
One pupil unreactive (%) 97 (3¢4) 2 (0¢3) 14 (1¢6) 81 (6¢1)
Two pupils unreactive (%) 144 (5¢0) 7 (1¢1) 4 (0¢4) 133 (10¢0)
Hypoxia (prehospital/ER) (%) 2709 184 (6¢4) 1 (0¢2) 15 (1¢7) 168 (12¢6)
Hypotension (prehospital/ER) (%) 2735 177 (6¢2) 3 (0¢5) 12 (1¢3) 162 (12¢2)
Any major extracranial injury (AIS >=3) (%) 2867 1032 (36¢0) 22 (3¢5) 262 (29¢1) 748 (56¢2)
CT characteristics
Any intracranial abnormality at central reading (%) 2867 1705 (59¢5) 86 (13¢5) 436 (48¢4) 1183 (88¢9)
Biomarker (median [IQR])
S100B, mg/L 2861 0¢15 [0¢08, 0¢33] 0¢09 [0¢05, 0¢15] 0¢09 [0¢06, 0¢16] 0¢28 [0¢16, 0¢58]
NSE, ng/ml 2858 17¢08 [12¢49, 25¢85] 14¢02 [11¢14, 18¢09] 14¢22 [11¢18, 19¢39] 23¢14 [16¢24, 34¢10]
GFAP, ng/ml 2850 3¢14 [0¢53, 15¢07] 0¢30 [0¢11, 0¢94] 1¢51 [0¢39, 5¢28] 12¢92 [4¢22, 34¢92]
UCH-L1, pg/ml 2846 94¢74 [35¢54, 307¢12] 35¢48 [17¢63, 63¢34] 51¢44 [24¢92, 109¢66] 274¢35 [119¢23, 622¢66]
Tau, pg/ml 2851 2¢79 [1¢23, 7¢67] 1¢16 [0¢71, 1¢84] 1¢81 [1¢05, 3¢45] 7¢08 [3¢21, 16¢61]
NFL, pg/ml 2849 18¢55 [8¢40, 49¢74] 7¢90 [5¢09, 13¢29] 12¢88 [7¢15, 24¢55] 42¢88 [19¢49, 104¢59]
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Sensitivity analyses were carried out on patients with GCS 1314,
in those with GCS 15, with major extracranial injuries (defined as
AIS>=3), and according to stratum (ER, admission, and ICU). In addi-
tion, AUCs were generated for samples collected at different times
post-injury (in 6-h intervals) to explore possible influence of sam-
pling time. Statistical analysis was performed using R (http://www.r-
project.org, version 3.5.1) in RStudio (http://www.rstudio.com, ver-
sion 1.1.456).
3. Results
3.1. Patient cohort and sampling
Data on 2867/4509 (64%) patients analyzed in the CENTER-TBI
Core study were available for analysis of biomarkers in serum sam-
ples obtained within 24 h of injury (Fig. 1). The time between injury
and sampling was shortest in the ER stratum (5¢1 h; IQR [3¢49¢73]),
in contrast to the admission (15¢7 h; IQR [9¢820¢2]) and ICU (14¢3 h;
IQR [7¢519¢7]) strata (Supplementary Fig. 1). The median needle to
freezer times was 1¢08 h (IQR [0¢921¢33]), with no substantial dif-
ferences across strata. Agreement between replicates of biomarker
assessments was good for the clinical platform assays of S100B and
NSE (CV: 7% for both on a log transformed scale), but poorer for the
research-use only (RUO) assays of GFAP, UCH-L1, NFL and t-tau (CV:
22-30%) (Supplementary Fig. 2).
Clinical characteristics of the study cohort, differentiated by stra-
tum, are summarized in Table 1 and the frequency of specific charac-
teristics, contained in CDRs for predicting CT abnormalities in
patients with mild TBI, presented in Supplementary Table 2. Charac-
teristics of patients excluded (n=1642; see Fig. 1) were largely similar
to those analyzed (n=2867), although the median GCS was lower
(14 vs 15) and the percentage of non-reacting pupils higher (9¢0% vs
5¢3%) (Supplementary Table 3).
3.2. Biomarker values by stratum and clinical severity
The median values of the six biomarkers displayed a clear associa-
tion with injury severity (classified according to the GCS) and care
path (Table 1, and Supplementary Table 4). Within the group of mild
TBI (GCS 1315), median values were higher in patients with a GCS
of 1314 compared to 15.
All biomarkers showed correlations across all strata, except for
NSE in the ER stratum with NFL and GFAP (Fig. 2). Correlations were
strongest in the ICU stratum, likely reflecting greater differences in
case-mix. The strongest correlation was found between UCH-L1 (neu-
ronal marker) and t-tau (axonal marker) varying from 0¢53 (ER) to
0¢86 (ICU). The correlation between GFAP and S100B, both glial
markers, was relatively weak, varying between strata from 0¢38 (ER)
to 0¢57 (ICU).
Fig. 2. Correlation plots displaying associations between biomarkers in each stratum. The diagonal part with the name of the biomarker contains the distribution plot specific
for the log-transformed biomarker. Scatter plots of correlations between biomarkers are presented below the diagonal, and Spearman correlation coefficients above the diagonal.
The font size is indicative of the strength of correlation.
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3.3. Biomarkers and traumatic intracranial CT abnormalities
Biomarker levels were higher in patients with traumatic abnor-
malities on CT scanning compared to those without (Fig. 3 and Sup-
plementary Table 5). Differences in biomarker levels between CT+ and
CT- patients were greater when analyzed by clinical severity (GCS)
than by care path. Differences were most pronounced for GFAP.
Univariable analysis confirmed that GFAP had the highest discrim-
ination for predicting the presence of CT abnormalities (AUC 0¢89
[95%CI: 0.870¢90]), and performed as well, and even better in the
admission stratum, as clinical characteristics (Supplementary Fig. 3
and Supplementary Table 6). Most other biomarkers showed substan-
tial discrimination, but performed poorer than clinical characteristics.
This finding was confirmed in the bootstrap analysis: the chance that
GFAP outperformed clinical characteristics was >99% in all sub-
groups, except for the ER stratum (Fig. 4). In the admission stratum,
UCH-L1, NFL and t-tau outperformed clinical characteristics in less
than 95% of the bootstrap samples. Combining all biomarkers showed
slightly higher discrimination compared to GFAP alone. We found no
clear benefit of any other combination of biomarkers, including the
combination of GFAP and UCH-L1 (Supplementary Fig. 4 and Supple-
mentary Table 7).
Multivariable analysis adjusted for clinical characteristics incorpo-
rated in CT rules confirmed that GFAP provided incremental discrimi-
native ability over clinical characteristics (increase from 0¢89 [95%CI:
0¢880¢90] to 0¢92 [95%CI: 0¢910¢93] when GFAP was included;
Fig. 5 and Supplementary Table 8). The incremental value was most
pronounced in the admission stratum (increase in AUC from 0¢72
[95%CI: 0¢690¢75] to 0¢84 [95%CI: 0¢810¢86]), and was consistent
in patients with a GCS of 15 (increase in AUC from 0¢83 [95%CI:
0¢800¢85] to 0¢88 [95%CI: 0¢860¢89]), and in those with a GCS of
1314 (increase in AUC from 0¢84 [95%CI: 0¢800¢88] to 0¢90 [95%CI:
0¢860¢92]). Combinations of biomarkers showed no clear increase
in discrimination compared to GFAP alone on multivariable analysis
(Supplementary Fig. 5 and Supplementary Table 9).
While profound differences in the performance of biomarkers
were not observed across different time intervals within 24 h of
injury, GFAP levels displayed the greatest incremental predictive
power when measured 1218 h post-injury. (Supplementary Fig. 6).
The incremental value of biomarkers was similar across patients
with major extracranial injury and those without major extracranial
injury (Supplementary Fig. 7).
Reclassification plots confirmed the incremental value of GFAP
across all strata compared to clinical characteristics (Fig. 6). Adding
GFAP correctly reclassified 71% of patients with a negative CT scan, and
70% of the patients with a positive CT scan. The plots show that when
added to the decision rule, GFAP levels often provide higher risk esti-
mates to patients who had lower predicted risks by clinical characteris-
tics. The same pattern, and similar extent of correct reclassification was
seen when all biomarkers were combined (Supplementary Fig. 8).
We further explored the discriminative value of biomarkers for
predicting abnormalities on MR imaging performed within 3 weeks
of injury in a subgroup of 152 patients who had a negative CT scan on
presentation and underwent subsequent MR imaging. Traumatic MR
abnormalities were found in 44/152 cases. The estimates were uncer-
tain, but GFAP showed the highest discriminative ability (c-statistic:
0¢76, 95% CI: 0¢670¢85, Supplementary Fig. 9 and Supplementary
Table 10).
4. Discussion
We studied the relation of serum biomarkers to clinical severity,
care path and the presence of traumatic intracranial abnormalities on
CT scanning. We found that all biomarkers studied scaled with injury
severity, classified according to the GCS and with care path intensity.
Within each of these stratifications, biomarkers were higher in
patients with abnormalities on head CT imaging compared to those
without. Serum GFAP levels in the first 24 h post-injury were highly
predictive for CT positivity, outperforming other markers and adding
value to clinical variables considered in contemporary CT decision
Fig. 3. Biomarker values by stratum and by clinical severity, differentiated for the absence (blue) or presence (pink) of traumatic intracranial CT abnormalities. P-values of
the MannWhitney U tests are presented in the Supplemental material, Table 11.
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rules. Combining results of all biomarkers did not clearly improve
discrimination compared to GFAP alone.
To the best of our knowledge, this is the first large scale study across
all injury severities, evaluating systematically a panel of 6 biomarkers,
and quantifying their performance relative to clinical characteristics in
predicting CT abnormalities in patients with mild TBI. Recently, Thelin
et al. reported on the same panel of biomarkers in a cohort of 172
patients with TBI [20]. The focus of this study was, however, on progno-
sis. Other previous studies have shown relations of biomarkers to clini-
cal severity and to the presence of CT abnormalities [2124]. Most,
however, mainly focused on one or two biomarkers and have seldom
addressed performance of biomarkers relative to clinical characteristics.
Moreover, a living systematic review identified serious problems in the
design, analysis and reporting of many of the studies [8]. Until recently,
the strongest evidence for a role in triaging CT scanning existed for
S100B. This marker is incorporated in the Scandinavian guidelines for
the management of moderate to minimal TBI [11]. Previously, a study
including 397 patients with general trauma, of whom 209 had mild TBI,
reported that GFAP performed better than S100B, in particular in
patients with extracranial injuries [21]. Our results expand these earlier
data, convincingly showing that GFAP outperforms S100B both in the
overall group of mild TBI and in the subset of patients with a GCS of 15.
However, we believe that a decision to replace S100B by GFAP in such
guidelines may be premature. Assays for S100B are commercially avail-
able with high reproducibility. Currently, no GFAP assays are available
as a commercialized clinical assay platform. Indeed, the platform we
used for analysis of GFAP is a research-use-only (RUO) platform, and
our replication assays showed substantial variation (28% on a log trans-
formed scale). Factors that may have contributed to poor reproducibility
include: not fully automated analyses, and that replicate samples had
undergone a second freeze-thaw cycle. There is no evidence that refrig-
erated storage of samples for up to 72 h has a significant effect on
GFAP values [25], but a decrease of GFAP levels has been reported in
CSF after two freeze-thaw cycles [26].
The clear effects of GFAP and other biomarkers in the presence of
assay heterogeneity speaks to the robustness of our findings. The role
of biomarkers goes beyond triage for CT scanning in patients with
mild TBI. Our results in this specific subgroup confirm the potential
of GFAP to predict presence of MRI abnormalities in patients with
normal CT findings after TBI [2].
4.1. Assay reproducibility and thresholds
Reliability and reproducibility of biomarker assays are fundamen-
tal for clinical implementation. Absolute GFAP levels in our study
were much higher than those reported in the ALERT-TBI study, which
used a different platform [13]. Whilst different reference values
between platforms may be acceptable, insight into comparability of
values obtained with different platforms is desirable. Variation
between platforms also precludes the concept of determining a uni-
versal cut-off value. Moreover, cut-off values are generally derived
from reference values, obtained from healthy controls, whilst “action
thresholds” are needed in diseased patients, which may be very dif-
ferent from reference values [27]. Further, it should be recognized
that any biomarker represents a continuous variable and that use of a
threshold value leads to loss of information. We suggest that bio-
markers may be combined with clinical characteristics for risk esti-
mation, and then continuous values may be retained. We have hence
refrained from suggesting threshold values, a decision which was
reinforced by the variability in replicate assays.
4.2. GFAP versus a multi-marker approach
Contrary to our expectations, a multi-marker approach applying
combinations of biomarkers did not increase the diagnostic value for CT
positivity, compared to GFAP alone. GFAP showed similar discrimination
as all biomarkers combined when analyzed versus clinical severity and
care path. Nevertheless, these observations do not preclude potential
usefulness of combinational approaches in terms of outcome prediction
and/or tracking the disease process over time. Conceptually, different
biomarkers should differentially reflect specific aspects of the disease
process of TBI [21,28]. However, in this study we did not find any bene-
fit of combining acute GFAP levels with UCH-L1 levels, a combination of
(presumed) glial and neuronal markers used in the recent ALERT-TBI
Fig. 4. Heat map demonstrating the discriminative ability of single biomarkers in comparison to a regression model that includes clinical characteristics contained in CT
decision rules. The heat map summarizes the percentage of bootstrap replicates in which the model with the biomarker outperforms (higher c-statistic) the model with CT decision
rule variables. The lower number of positive replicates for GFAP in the ER stratum may be due to lower number of events in this stratum (86/636 CT positive).
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trial, which provided the basis for a recent FDA marketing authorization
[9,13]. Our results provide no support for implementation of this com-
bined assay into clinical practice. We do note, however, that a key dif-
ference between our study and ALERT-TBI is that the time window for
blood sampling was 24 h in our study and 12 h in ALERT-TBI. This may
be relevant as the half-life for UCH-L1 is short [29]. However, sensitivity
analysis differentiated for time of sampling (Supplementary Fig. 6) did
not show superior performance of UCH-L1 in the first six hours after
trauma. The finding that a single marker approach (GFAP) may be suffi-
cient in the acute phase to inform diagnosis and care path is of particu-
lar relevance for low and middle income countries (LMICs) and other
austere environments, where even basic imaging is inaccessible, or too
expensive and unevenly distributed, with limited opportunities for
patient transfer.
4.3. Strengths and limitations
Strengths of our study include the large number of patients, anal-
yses across all severities of TBI, the use of a comprehensive panel of
biomarkers that addresses current clinical interest and the focus on
the incremental value of biomarkers in predicting CT positivity com-
pared to clinical characteristics used in CDRs. These strengths support
the generalizability of our findings, obtained in the “real-world” situ-
ation of an observational study.
Several limitations of our study should be acknowledged:
First, our study should be considered as an exploratory diagnostic
accuracy study [27], and was not designed to seek regulatory
approval.
Second, we were able to analyze samples from 2867/4509 (64%)
patients available in the CENTER-TBI database. Although baseline
characteristics of the study cohort were very similar to those
reported for the Core study (n=4509) [15], we here included
slightly less severe patients.
Third, we utilized a research-use only (RUO) platform for assays of
four biomarkers (GFAP, UCH-L1, NFL and t-tau), and coefficients
of variation in replicate samples were relatively high.
Fourth, the inclusion criteria for CENTER-TBI included the intent to
perform a CT scan. As a consequence, the patient population may
have been biased towards inclusion of more patients with CT
abnormalities. However, overall 40% of patients were CT negative
(86% in ER, 52% in Admission and 11% in the ICU stratum).
Fifth, the reported interpretation of results is only valid for the bio-
markers studied and cannot be extrapolated to other biomarkers.
CENTER-TBI has prepared for facilitating legacy research on other
markers or on clinical-use platform(s) by reserving a number of
pristine aliquots for future studies.
Sixth, the permitted time window of 24 h may have affected the diag-
nostic accuracy of biomarkers with short circulating half-lives.
Understanding the kinetics of such biomarkers may [30,31]
inform optimization of time windows for improving diagnostic
performance.
Seventh,we did not explore possible gender effects.
Eighth, we did not take the clustered structure of the data into
account, because it was statistically not feasible to adjust both for
clinical characteristics as well for between center variations.
Finally, as explained above, we deliberately refrained from attempt-
ing to identify action thresholds (cutoff values) in a post-hoc
analysis.
In conclusion, each of the six investigated biomarkers scaled with
the severity of TBI and with care path. GFAP serum levels obtained
within 24 h post-injury predict CT positivity across the full range of
injury severities. In patients with mild TBI and in patients with a GCS
Fig. 5. Incremental discriminative ability of biomarkers to predict CT positivity. Plots show the difference in Area under the ROC curve (AUC) with 95% confidence intervals
(bars) of logistic regression models combining age, time interval (injury to needle time) as well as clinical parameters included in current CT rules with and without biomarkers.
Panels are presented for the overall sample (n=2867), according to stratum (ER, Admission, ICU), and for the mild (GCS 1315; GCS 1314; GCS 15) groups. Six biomarkers are con-
sidered separately and in combination (“all”). The dotted line indicates the predictive value of the clinical parameters and serves as a reference. The absolute values are presented in
the Supplementary material, Table S7.
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of 15, GFAP adds value to clinical characteristics and outperforms
other markers, including S100B. No clear additional value for predict-
ing CT positivity was found when combining GFAP with other bio-
markers. Our evidence supports development of novel CT decision
rules, combining serum GFAP with clinical characteristics, for triaging
patients with mild TBI for CT scanning. To this purpose, validated
clinical-use assays are required.
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